Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 6 | 2023 | 399 | 1.000 |
Why?
|
| Brachytherapy | 3 | 2021 | 132 | 0.820 |
Why?
|
| Genital Neoplasms, Female | 3 | 2021 | 99 | 0.790 |
Why?
|
| Brain Neoplasms | 5 | 2023 | 1329 | 0.600 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2020 | 149 | 0.570 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 1149 | 0.500 |
Why?
|
| Glioblastoma | 4 | 2023 | 353 | 0.470 |
Why?
|
| Endometrial Neoplasms | 2 | 2021 | 205 | 0.280 |
Why?
|
| Radiotherapy Dosage | 2 | 2021 | 288 | 0.180 |
Why?
|
| Fitness Trackers | 1 | 2021 | 17 | 0.170 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2020 | 74 | 0.160 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2021 | 49 | 0.160 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2019 | 41 | 0.150 |
Why?
|
| Reminder Systems | 1 | 2021 | 140 | 0.150 |
Why?
|
| Quality of Life | 3 | 2021 | 3204 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 969 | 0.140 |
Why?
|
| Efficiency, Organizational | 1 | 2018 | 141 | 0.130 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 413 | 0.130 |
Why?
|
| Dacarbazine | 1 | 2017 | 100 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2017 | 149 | 0.120 |
Why?
|
| Anesthesia | 1 | 2020 | 256 | 0.120 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 8333 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2021 | 8057 | 0.110 |
Why?
|
| Time Factors | 3 | 2020 | 7123 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 1323 | 0.100 |
Why?
|
| Disease Progression | 2 | 2017 | 2864 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1189 | 0.090 |
Why?
|
| Aged | 7 | 2021 | 26153 | 0.090 |
Why?
|
| Female | 11 | 2021 | 78845 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2021 | 17291 | 0.080 |
Why?
|
| Treatment Outcome | 3 | 2021 | 11772 | 0.080 |
Why?
|
| Middle Aged | 7 | 2021 | 36215 | 0.080 |
Why?
|
| Humans | 14 | 2023 | 145475 | 0.080 |
Why?
|
| Exercise | 1 | 2021 | 2198 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 2664 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2022 | 1471 | 0.060 |
Why?
|
| Chemoradiotherapy | 2 | 2020 | 239 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 3904 | 0.060 |
Why?
|
| Adult | 5 | 2023 | 40777 | 0.060 |
Why?
|
| Brain | 1 | 2017 | 2947 | 0.050 |
Why?
|
| Male | 6 | 2021 | 72843 | 0.050 |
Why?
|
| Nephrons | 1 | 2021 | 23 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2023 | 767 | 0.040 |
Why?
|
| Electronic Mail | 1 | 2021 | 60 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2021 | 249 | 0.040 |
Why?
|
| Telephone | 1 | 2021 | 177 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2022 | 324 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2022 | 1266 | 0.040 |
Why?
|
| Text Messaging | 1 | 2021 | 182 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2019 | 6013 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 779 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 381 | 0.030 |
Why?
|
| Walking | 1 | 2021 | 542 | 0.030 |
Why?
|
| Cancer Survivors | 1 | 2021 | 337 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 423 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1374 | 0.030 |
Why?
|
| Kidney | 1 | 2021 | 1497 | 0.020 |
Why?
|
| Survivors | 1 | 2017 | 523 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 2923 | 0.020 |
Why?
|
| Communication | 1 | 2017 | 975 | 0.020 |
Why?
|
| Risk Factors | 1 | 2021 | 10885 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 6066 | 0.010 |
Why?
|